PART I: SETTING THE SCENE.

Pharmaceutical Research: For What, for Whom? Science and Social Policies (D. J. Triggle).

Property-Based Lead Optimization (H. van de Waterbeemd).

PART II: BIOLOGICAL STRATEGIES.

Membranes - From Barriers to Magic Bullets (O. G. Mouritsen).

Cell Culture Absorption Models - State of the Art (P. Artursson, P. Matsson).

Metabolic Studies in Drug Research and Development (B. Neugnot, M.-J. Bossant, F. Caradec, B. Walther).

In vitro, in vivo and in silico Approaches to Predict Induction of Drug Metabolism (U. A. Meyer, S. Blättler, C. Gnerre, M. Oscarson, A.-K. Peyer, F. Rencurel, O. Rifki, A. Roth).

Coordination of Uptake and Efflux Transporters in Drug Disposition (H. Kusuhara, Y. Sugiyama).

The Role of Plasma Protein Binding in Drug Discovery (R. E. Fessey, R. P. Austin, P. Barton, A. M. Davis, M. C. Wenlock).

In vivo Pharmacokinetic Profiling of Drugs (H. Wunderli-Allenspach).

PART III: PHYSICOCHEMICAL STRATEGIES.

Automated Parallel Synthesis in Support of Early Drug Discovery: Balancing Accessibility of Chemistry with the Design of Drug-like Libraries (C. M. Baldino).

New Insights into the Lipophilicity of Ionized Species (G. Caron, G. Ermondi).

Physicochemical and Biological Profiling in Drug Research. ElogD(7.4) 20,000 Compounds later: Refinements, Observations and Applications (F. Lombardo, M. Y. Shalaeva, B. D. Bissett, N. Chistokhodova).

Lipid Bilayers in ADME: Permeation Barriers and Distribution Compartments (S. D. Krämer).

High-throughput Solubility, Permeability, and the MAD PAMPA Model (A. Avdeef).

Correlations between PAMPA Permeability and Log P (K. Box, J. Comer, F. Huque).

Predicting the Intestinal Solubility of Poorly Soluble Drugs (A. Glomme, J. März, J. B. Dressman).

Accelerated Stability Profiling in Drug Discovery (E. H. Kerns, L. Di).

Physicochemical Characterisation of the Solid State in Drug Development (D. Giron).

PART IV: COMPUTATIONAL STRATEGIES.

Calculation of Lipophilicity: A Classification of Methods (R. Mannhold).

The Concept of Property Space: The Case of Acetylcholine (G. Vistoli, A. Pedretti, L. Villa, B. Testa).

Prediction of Site of Metabolism in Humans: Case Studies of Cytochromes P450 2C9, 2D6 and 3A4 (G. Cruciani, R. Vianello, I. Zamora).

Use of Pharmacophores in Predictive ADME (O. O. Clement, O. F. Güner).

The BioPrint® Approach for the Evaluation of ADME-T Properties: Application to the Prediction of Cytochrome P450 2D6 Inhibition (R. Gozalbes, F. Barbosa, N. Froloff, D. Horvath).

Using Computer Reasoning about Qualitative and Quantitative Information to Predict Metabolism and Toxicity (P. Judson).

Physiologically Based Pharmacokinetic Models (T. Lavé, H. Jones, N. Paquerau, P. Poulin, P. Theil, N. Parrott).

Processing of Biopharmaceutical Profiling Data in Drug Discovery (K. Sugano, R. Saitoh, A. Higashida, H. Hamada).

PART V: CONCLUDING CHAPTERS.

Educational and Communication Issues Related to Profiling Compounds for Their Drug-Like Properties (R. T. Borchardt).

Present and Future Significance of ADMET Profiling in Industrial Drug Research (W. Cautreels, M. de Vries, C. H?, H. Koster, L. Turski).

Index.